Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
September 25 2023 - 9:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced the appointment of Caren Deardorf
as the Company’s first Chief Commercial and Strategy Officer. Ms.
Deardorf will build and lead Editas Medicine’s commercial
organization, strategy, and execution to support all launch,
commercialization, and lifecycle management activities of the
Company’s current and future pipeline of products.
“As we drive our lead program EDIT-301 towards
commercialization, I am happy to welcome a commercial leader of
Caren’s caliber to Editas. Caren has a proven ability to translate
early discovery and clinical assets into robust business strategy
with disciplined portfolio prioritization and value creation.
Additionally, she has led multiple successful US and global product
launches. Caren’s expertise and track record make her the ideal
leader to help Editas reach this goal for patients,” said Gilmore
O’Neill, M.B., M.M.Sc., President and Chief Executive Officer,
Editas Medicine.
Ms. Deardorf added, “With a clear focus on bringing EDIT-301
into the market for people living with sickle cell disease, ‘right
now’ is the optimal time for Editas to build a commercial team and
strategy. I look forward to driving the business forward alongside
this strong Leadership Team as we bring EDIT-301 – and future
pipeline medicines – through the clinic to commercialization.”
Caren Deardorf brings to Editas more than 25 years of
international biotechnology leadership across a range of companies
and therapeutic areas. Most recently, Ms. Deardorf served as the
Chief Commercial Officer of Magenta Therapeutics. Prior to Magenta,
she served as the Chief Commercial Officer of Ohana Biosciences
where she was responsible for developing a commercial strategy,
including planning for the company’s first product launch.
Earlier in her career, Ms. Deardorf held a variety of commercial
roles of increasing responsibility at Biogen, most recently serving
as Vice President, Product Development & Commercialization,
leading and executing a highly successful global launch of
SPINRAZA®, a treatment for children and adults with spinal muscular
atrophy. During her tenure at Biogen, Ms. Deardorf was instrumental
in building the multiple sclerosis (MS) franchise and helping to
establish Biogen’s global leadership through US and worldwide brand
management, including leading the brand and launch strategy for
TECFIDERA® and the successful US and EU launches of TYSABRI® and
AVONEX®.
Ms. Deardorf holds a Bachelor of Science degree in biology from
Tufts University and a Master of Business Administration from the
Olin Graduate School of Business at Babson College. Ms. Deardorf
serves on the Boards of Directors for Crinetics Pharmaceuticals and
for NeuroSense Therapeutics. She is also a board member for the
Pan-Mass Challenge, a non-profit organization that raises funds for
Dana-Farber Center Institute.
About Editas MedicineAs a
clinical-stage genome editing company, Editas Medicine is focused
on translating the power and potential of the CRISPR/Cas12a and
CRISPR/Cas9 genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the
world. Editas Medicine aims to discover, develop, manufacture, and
commercialize transformative, durable, precision genomic medicines
for a broad class of diseases. Editas Medicine is the exclusive
licensee of Broad Institute’s Cas12a patent estate and Broad
Institute and Harvard University’s Cas9 patent estates for human
medicines. For the latest information and scientific presentations,
please visit www.editasmedicine.com.
Forward-Looking StatementsThis press release
contains forward-looking statements and information within the
meaning of The Private Securities Litigation Reform Act of 1995.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "target," "should," "would," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. The
Company may not actually achieve the plans, intentions, or
expectations disclosed in these forward-looking statements, and you
should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in these
forward-looking statements as a result of various important
factors, including: uncertainties inherent in the initiation and
completion of preclinical studies and clinical trials, and clinical
development of the Company’s product candidates; availability and
timing of results from preclinical studies and clinical trials;
whether interim results from a clinical trial will be predictive of
the final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to
market products and availability of funding sufficient for the
Company’s foreseeable and unforeseeable operating expenses and
capital expenditure requirements. These and other risks are
described in greater detail under the caption “Risk Factors”
included in the Company’s most recent Annual Report on Form 10-K,
which is on file with the Securities and Exchange Commission,
as updated by the Company’s subsequent filings with
the Securities and Exchange Commission, and in other filings
that the Company may make with the Securities and Exchange
Commission in the future. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and the Company expressly disclaims any obligation to update any
forward-looking statements, whether because of new information,
future events or otherwise.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1a4cdbf9-9748-4d22-95b6-c03e4665de73
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Oct 2023 to Oct 2024